Emulating the MERINO trial analysis dataset

This dataset contains data on the 121 participants who met the eligibility criteria and were included in the analysis of the emulation of the MERINO trial (Evans et al.). Patients were included if they had a BSI with E. coli or Klebsiella spp. that was resistant to Ceftriaxone and/or Cefotaxime and susceptible to both meropenem and piperacillin-tazobactam and treatment was started within 72 hours of blood culture. Patients that would have otherwise been eligible but did not start any of the study drugs (meropenem or piperacillin-tazobactam) within the 72 hours window were considered ineligible and excluded from the emulated trial population. All participants were aged 18 years and over. Polymicrobial infections and repeat episodes were excluded.

本数据集收录了符合入组标准、被纳入MERINO试验（埃文斯等[Evans et al.]）复刻分析的121名受试者的相关数据。入组受试者需满足：罹患大肠埃希菌（E. coli）或克雷伯菌属（Klebsiella spp.）血流感染（BSI, Bloodstream Infection），且该菌株对头孢曲松（Ceftriaxone）和/或头孢噻肟（Cefotaxime）耐药，同时对美罗培南（meropenem）及哌拉西林-他唑巴坦（piperacillin-tazobactam）均敏感，并在血培养后72小时内启动抗菌治疗。若受试者原本符合入组条件，但未在72小时窗口期内使用本研究规定药物（美罗培南或哌拉西林-他唑巴坦），则视为不符合入组标准，被排除出该复刻试验的研究人群。所有受试者年龄均为18周岁及以上。多重菌感染及复发感染病例均被排除。